118 filings
8-K
XFOR
X4 Pharmaceuticals Inc
22 May 24
Regulation FD Disclosure
8:09am
8-K
XFOR
X4 Pharmaceuticals Inc
9 May 24
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105
6:58am
8-K
XFOR
X4 Pharmaceuticals Inc
7 May 24
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
6:28am
8-K
XFOR
X4 Pharmaceuticals Inc
29 Apr 24
Regulation FD Disclosure
8:30am
8-K
XFOR
X4 Pharmaceuticals Inc
29 Apr 24
X4 Pharmaceuticals Announces FDA Approval of XOLREMDIâ„¢ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
6:30am
8-K
7luay55czl35r iums
5 Apr 24
Other Events
4:30pm
8-K
6lpcb mk5swv0i3
1 Apr 24
Regulation FD Disclosure
9:20am
8-K
iblougo8phyhj
21 Mar 24
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial
7:43am
8-K
z3nlh3oe3ml2w2
8 Jan 24
Regulation FD Disclosure
4:08pm
8-K
pn25k5pp 06nu6xv8ca
27 Nov 23
Regulation FD Disclosure
5:20pm
8-K
auma olk83mmnr
14 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:10pm
8-K
d5a59k9c72h3z
9 Nov 23
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
8:07am
8-K
wg0bhrl32mg ynltgpn
31 Oct 23
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome
4:25pm
8-K
5d6j 11ogmns05lpx
18 Oct 23
X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors
8:17am
8-K
lgn7s
5 Sep 23
X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome
5:00pm
8-K
0xvq7xx4j h7x2814f
10 Aug 23
Provides Corporate Updates, and Reports Emerging Data from
6:41am
8-K
jvhdb71g dmf
3 Aug 23
X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital
4:41pm
8-K
hrcfq1ueow
15 Jun 23
Submission of Matters to a Vote of Security Holders
4:38pm
8-K
wfxij lpg28yz8vn
1 Jun 23
Regulation FD Disclosure
4:16pm
8-K
afpne5ti4cggay8 r8h
16 May 23
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
4:24pm